JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Benitec Biopharma (BNTC – Research Report) today and set a price target of $18.00.
Silvan Tuerkcan has given his Buy rating due to a combination of factors surrounding Benitec Biopharma’s promising developments in their gene therapy program. The company is set to present new data at the MDA Conference, which could further validate their innovative silence and replace strategy, potentially leading to significant growth through 2025. The interim study results for the first three patients treated with BB-301 show durable and clinically significant reductions in dysphagic deficits, with no severe adverse events reported.
Furthermore, Benitec Biopharma has demonstrated efficacy in previous patients with different manifestations of the condition, indicating a broad potential for their treatment. The anticipation of further updates, particularly with the initiation of a high-dose cohort later in 2025, supports the optimistic outlook. The consistent improvements observed in patient outcomes and the strategic advancements in their clinical trials underpin the Buy rating, with a DCF-derived price target of $18.